Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06334302
Other study ID # RMC0362-23ctil
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date March 25, 2024
Est. completion date April 25, 2024

Study information

Verified date March 2024
Source Rabin Medical Center
Contact Alona Hamou, Msc
Phone 972-3-9253778
Email alonah@clalit.org.il
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Omega Galil has developed a novel fatty sweetener that allows the use of up to 80% less sugar (particularly sucrose) and yet achieves a natural sweet flavor, using a novel technology of milling the natural sucrose crystals together with oil and thus creating a micro-suspension of sugar in oil or fat. The suspension increases the surface area of the sugar particles and thus a lower quantity of sugar is required in order to reach an enhanced perception of sweetness at the sweet taste receptors in the mouth. Omega Galil provides fatty food products that use up to 80% less sucrose, while tasting as sweet as regular sugar sweetened foods, with no aftertastes of sugar substitutes, and no chemical modifications or additives. Postprandial glucose (PPG) excursions in Type 1 Diabetes happen mainly due to a delay in subcutaneous insulin absorption and action, but also among other factors, depend on the meal composition. The glycemic index (GI) ranks foods based on acute glycemic response over a 2-h period of 50 g of available carbohydrates (CHO) of a test food compared with the reference standard glucose. Glycemic Load (GL) is a GI-weighted measure of carbohydrate content, which estimates the impact of carbohydrate intake using the GI while taking into account the amount of carbohydrates that are eaten in a serving. Several studies have demonstrated differences in PPG after consumption of low versus high GI meals, with rapid glucose spikes following high GI meals . Helping people with T1D achieve a diet with a lower glycemic load can improve both their quality of life and their diabetes-associated complications. The proposed randomized, double blind, cross-over, active control, clinical trial aims to: 1. compare the glycemic response of T1D subjects to 20 grams of the O'Sweet sugar-reduced spread containing 8% sugar and a total of 1.6 grams of sucrose per meal, with their glycemic response to 20 grams of control Nutella spread, containing 56% sugar and a total of 11 grams sucrose per meal. 2. compare the acceptance ("Not sweet enough, just right or too sweet") Labeled Magnitude score of O'Sweet compared to the control spread (Nutella).


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date April 25, 2024
Est. primary completion date April 25, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 35 Years
Eligibility Inclusion Criteria: - T1D patients with diabetes duration >1 year - 18-35 years of age - Normal weight (BMI 20- 30 kg/m2) - Non-smoker - Hemoglobin A1C <9% - Patient treated with Continuous Glucose Monitoring system (CGM's) Exclusion Criteria: - Acute Upper Respiratory Tract Infection (URTI) within 2 weeks of enrollment - A gastro-intestinal condition that could disrupt intestinal absorption or motility, and thereby impair postprandial glucose absorption (e.g. diabetic gastroparesis, celiac disease, or malabsorption). - A chronic illness in the past 5 years, including among others inflammatory, metabolic, neoplastic, and congenital disease. - Use of medications other than insulin (e.g. Antibiotics/antifungal, analgesics) during the study and 2 weeks before enrollment; - Neuro-psychiatric disorders - Known food allergies or intolerances - Self-reported sinus, taste or smell dysfunction - Pregnant or lactating women

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Omega Galil Hazelnut Chocolate Spread "O'Sweet Spread"
Omega Galil O'Sweet hazelnut cocoa spread is composed of 8% sucrose, 26% MCT oil, 6% cocoa butter, 6% cocoa powder, 10% Hazelnut paste, 24% fibers, 13% rice flour. It contains a total of 27.3 gram carbohydrates/ 100gram, 520 kcals/100 grams, and very low estimated GL according to healthy adults
Active Control-Nutella hazelnut cocoa spread
Nutella hazelnut cocoa spread is composed of 56% sugar, 30% vegetable fat, 13% Hazelnut paste, milk powder (8.7%), and cocoa powder (7.4%), containing a total of 57.5 grams carbohydrates /100grams, 532 kcals/100 grams, and an estimated GL of 4

Locations

Country Name City State
Israel Schneider Children Medical Center of Israel Petach-Tikva

Sponsors (2)

Lead Sponsor Collaborator
Rabin Medical Center Omega 3 Galilee

Country where clinical trial is conducted

Israel, 

Outcome

Type Measure Description Time frame Safety issue
Primary Delta postprandial glucose level The difference between pre-meal and peak postprandial glucose level in each of the two 2 hours' meal tests. first meal teat visit 1 (day 1) and second meal test visit 2 (2 weeks)
Secondary Incremental area under the curve (iAUC) Incremental area under the curve (iAUC) using continuous glucose sensor data > 180 mg/dl between the beginning of the meal and 2 hours postprandial (defined as the postprandial period). first meal teat visit 1 (day 1) and second meal test visit 2 (2 weeks)
Secondary Peak postprandial glucose level The peak postprandial glucose level during the 2-hour postprandial period first meal teat visit 1 (day 1) and second meal test visit 2 (2 weeks)
Secondary Time in range (TIR) of 70-180 mg/dl Time in range (TIR) of 70-180 mg/dl during the postprandial period first meal teat visit 1 (day 1) and second meal test visit 2 (2 weeks)
Secondary Percentage of subjects who reached the desired glucose target The percentage of subjects who reached the desired glucose target (70-180 mg/dl) during the postprandial period (70% of the time) first meal teat visit 1 (day 1) and second meal test visit 2 (2 weeks)
Secondary The percentage of time spent above 180 mg/dl The percentage of time spent above 180 mg/dl first meal teat visit 1 (day 1) and second meal test visit 2 (2 weeks)
Secondary The percentage of time spent above 250 mg/dl The percentage of time spent above 250 mg/dl first meal teat visit 1 (day 1) and second meal test visit 2 (2 weeks)
Secondary The percentage of time spent above 350 md/dl The percentage of time spent above 350 md/dl first meal teat visit 1 (day 1) and second meal test visit 2 (2 weeks)
Secondary Labeled Magnitude Scale (gLMS) Acceptance of the sweetness level Labeled Magnitude Scale (gLMS) first meal teat visit 1 (day 1) and second meal test visit 2 (2 weeks)
See also
  Status Clinical Trial Phase
Completed NCT03886974 - Transition to Adult Care in Type 1 Diabetes
Completed NCT05620251 - Response to BNT162b2 Vaccine in Adolescents With Type 1 Diabetes
Completed NCT03623113 - The Dietary Education Trial in Carbohydrate Counting (DIET-CARB Study in Type 1 Diabetes N/A
Active, not recruiting NCT05078658 - Low-carbohydrate Diet in Children With Type 1 Diabetes N/A
Not yet recruiting NCT06018324 - CloudCare in the Treatment of Type 1 Diabetes in Pediatrics
Withdrawn NCT03736083 - Introducing CGM at Type 1 Diabetes Diagnosis N/A
Completed NCT03177096 - Impact of the Continuous Measurement of Blood Glucose on Insulin Pump on Child Quality of Life With Type 1 Diabetes N/A
Completed NCT04172077 - Self Efficacy Levels, Attachment Style and Resiliency of Youth With Type 1 Diabetes
Recruiting NCT04950634 - Sexual Dimorphism in Cardiovascular Autonomic Neuropathy in Patients With Type 1 Diabetes
Completed NCT04450745 - Physical Exercise in Normobaric Hypoxia and Normoxia in Type 1 Diabetic Patients N/A
Completed NCT03165786 - A Cognitive Behavioral Intervention to Reduce Fear of Hypoglycemia in Young Adults With Type 1 Diabetes N/A
Terminated NCT04028960 - IN Insulin in Type 1 Diabetes (T1D) Hypoglycemia Unawareness: Safety Only Phase Phase 2
Recruiting NCT05324488 - Diabetes Registry Graz for Biomarker Research
Completed NCT02984709 - Check It! 2.0: Positive Psychology Intervention for Adolescents With Type 1 Diabetes N/A
Completed NCT02984514 - Brown Adipose Tissue in Type 1 Diabetes N/A
Recruiting NCT06372392 - Universal Fixed Meal Boluses Usage in Patients With Medtronic Minimed 780G Pumps N/A
Recruiting NCT05973799 - Effect of Fasting on Hypoglycemic Counterregulation in Type 1 Diabetes N/A
Recruiting NCT03311516 - New Insulin Therapy by Multiwave Bolus N/A
Completed NCT03711656 - Prediction and Prevention of Nocturnal Hypoglycemia in Persons With Type 1 Diabetes Using Machine Learning Techniques N/A
Recruiting NCT05737654 - The Effect of Exercise on Metabolic Parameters, Anthropometric Measurement Values and Quality of Life N/A